文献速递母胎医学产科

复杂性单绒毛膜妊娠中射频消融选择性减胎在16孕周前与16孕周及之后的结局比较

Outcome of radiofrequency ablation for selective fetal reduction before vs at or after 16 gestational weeks in complicated monochorionic pregnancy.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-07-06

单中心回顾性分析2011年1月至2019年10月63例复杂性单绒毛膜妊娠射频消融选择性减胎术,26例(41.3%)在16周前、37例(58.7%)在16周及之后进行。共17例(27.0%)发生保留胎儿丢失,消融周期≥4次是唯一相关因素(P=0.035;OR 5.21);16周前与16周及之后相比,保留胎儿丢失率(23.1% vs 29.7%;P=0.558)、34周前未足月胎膜早破率(7.7% vs 5.4%;P=0.853)及分娩中位孕周(36.2 vs 37.3周;P=0.706)均无差异。

要点

  • 消融周期≥4次与射频消融后保留胎儿丢失相关(P=0.035;OR 5.21)。
  • 16周前与16周及之后行射频消融,保留胎儿丢失率无差异(23.1% vs 29.7%;P=0.558)。
  • 16周前与16周及之后行射频消融,分娩中位孕周无差异(36.2 vs 37.3周;P=0.706)。

核心结论

  • 射频消融是16周前早期选择性减胎有前景的工具,消融周期≥4次是保留胎儿丢失的主要风险因素,术前术后仔细评估并熟练操作以减少消融周期是保证该手术有效安全的关键。

研究设计与样本

  • 单中心回顾性分析,纳入2011年1月至2019年10月在本机构连续进行的63例复杂性单绒毛膜妊娠射频消融选择性减胎术。
  • 减胎指征包括双胎反向动脉灌注序列13例、双胎输血综合征12例、双胎贫血-红细胞增多序列2例、选择性胎儿生长受限10例、不一致畸形17例及三胎或四胎中含单绒毛膜双胎的多胎妊娠减胎9例。
  • 26例(41.3%)在16周前、37例(58.7%)在16周及之后手术;先单因素后多因素分析孕周、多胎顺序、羊膜性、指征及消融周期数对保留胎儿丢失风险的影响。

主要发现

  • 共17例(27.0%)发生保留胎儿丢失。
  • 消融周期≥4次是所研究因素中唯一与射频消融后保留胎儿丢失相关的因素(P=0.035;OR 5.21)。
  • 射频消融指征、多胎顺序、羊膜性及射频消融时孕周对保留胎儿丢失无影响。
  • 16周前与16周及之后行射频消融相比,保留胎儿丢失率无差异(23.1% vs 29.7%;P=0.558)。
  • 16周前与16周及之后行射频消融相比,34周前未足月胎膜早破率无差异(7.7% vs 5.4%;P=0.853),分娩中位孕周无差异(36.2 vs 37.3周;P=0.706)。

关键数值与推荐

  • 消融周期≥4次与保留胎儿丢失相关(P=0.035;OR 5.21)。
  • 16周前与16周及之后行射频消融,保留胎儿丢失率23.1% vs 29.7%(P=0.558)。
  • 16周前与16周及之后行射频消融,34周前未足月胎膜早破率7.7% vs 5.4%(P=0.853)。
  • 16周前与16周及之后行射频消融,分娩中位孕周36.2 vs 37.3周(P=0.706)。

临床怎么用

  • 作者认为射频消融是16周前早期选择性减胎有前景的工具。
  • 作者认为术前术后仔细评估并熟练操作以减少消融周期是保证手术有效安全的关键。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether gestational age at intervention (< or ≥ 16 weeks) and other factors affect the risk of loss of the cotwin after selective fetal reduction using radiofrequency ablation (RFA) in monochorionic (MC) pregnancy. METHODS: This was a single-center retrospective analysis of 63 consecutive RFA procedures performed at our institution from January 2011 to October 2019 for selective fetal reduction in complicated MC pregnancies. Indications for RFA were twin reversed arterial perfusion sequence (13 cases), twin-to-twin transfusion syndrome (12 cases), twin anemia-polycythemia sequence (two cases), selective fetal growth restriction (10 cases), discordant anomalies (17 cases) and multifetal pregnancy reduction in triplets or quadruplets with a MC pair (nine cases). Twenty-six (41.3%) of these procedures were performed before and 37 (58.7%) after 16 weeks. Potential factors that could affect the risk of loss of the cotwin, including gestational age at RFA, order of multiple pregnancy, amnionicity, indication for RFA and number of ablation cycles, were assessed first by univariate analysis and then by multivariate analysis. RESULTS: There were 17 (27.0%) cotwin losses. Ablation cycles numbering four or more was the only factor among those investigated to be associated with loss of the cotwin after RFA (P = 0.035; odds ratio, 5.21), while the indication for RFA, order of multiple pregnancy, amnionicity and gestational age at RFA had no effect. Comparing RFA performed at < 16 vs ≥ 16 weeks, there was no difference in the rate of cotwin loss (23.1% vs 29.7%; P = 0.558) or preterm prelabor rupture of the membranes before 34 weeks (7.7% vs 5.4%; P = 0.853), or in the median gestational age at delivery (36.2 vs 37.3 weeks; P = 0.706). CONCLUSIONS: RFA is a promising tool for early selective fetal reduction in MC pregnancy before 16 weeks. Four or more ablation cycles is a major risk factor for cotwin loss. Careful assessment pre- and post-RFA, together with proficient operative skills to minimize the number of ablation cycles, are the mainstay to ensure that this procedure is effective and safe. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ting YH, Poon LCY, Tse WT, et al. Outcome of radiofrequency ablation for selective fetal reduction before vs at or after 16 gestational weeks in complicated monochorionic pregnancy. Ultrasound Obstet Gynecol. 2021. PMID: 32730679. doi:10.1002/uog.22160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。